Recombinant interferon alfa-2b treatment in chronic non-A, non-B/type C hepatitis
- PMID: 8314477
- PMCID: PMC1374035
- DOI: 10.1136/gut.34.2_suppl.s126
Recombinant interferon alfa-2b treatment in chronic non-A, non-B/type C hepatitis
Abstract
In a study of 60 patients with non-A, non-B/type C (NANB/C) chronic hepatitis alanine aminotransferase (ALT) activities returned to normal after treatment with interferon alfa-2b (3 million units for six months) in 70.7% and 29.3% did not respond. The response was maintained during four to six months, follow up in 41.4% of patients. Liver biopsy specimen showed histological improvement in all patients surveyed. Treatment was well tolerated with only mild side effects.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical